The US Food and Drug Administration (USFDA) has granted final approval to Zydus Lifesciences to market Bisoprolol Fumarate and Hydrochlorothiazide tablets USP, 2.5 mg/6.25 mg, 5 mg/6.25 mg, and 10 mg/6.25 mg (USRLD: Ziac tablets).
High blood pressure should be treated with a combination of bisoprolol fumarate and hydrochlorothiazide (hypertension).
The group’s formulation manufacturing facility in Ahmedabad SEZ, India, will produce the medication.